Free Trial
→ Watch This Robotics Demo Before March 17th (From Brownstone Research) (Ad)

Immunome Q1 2023 Earnings Report

Immunome logo
$9.53 -0.58 (-5.73%)
As of 02/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Immunome EPS Results

Actual EPS
-$0.35
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Immunome Revenue Results

Actual Revenue
$2.36 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immunome Announcement Details

Quarter
Q1 2023
Date
5/5/2023
Time
N/A

Conference Call Resources

Powered by Quartr

Immunome Earnings Headlines

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 6, 2025 | businesswire.com
Insider Stock Buying Reaches US$2.82m On Immunome
February 4, 2025 | uk.finance.yahoo.com
Watch This Robotics Demo Before March 17th
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
February 22, 2025 | Brownstone Research (Ad)
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 31, 2025 | finance.yahoo.com
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
January 31, 2025 | businesswire.com
Immunome Can Take The Fight To Competitors With Varegacestat
January 30, 2025 | seekingalpha.com
See More Immunome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email.

About Immunome

Immunome (NASDAQ:IMNM), a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

View Immunome Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles